AR069747A1 - Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion - Google Patents
Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacionInfo
- Publication number
- AR069747A1 AR069747A1 ARP080105136A ARP080105136A AR069747A1 AR 069747 A1 AR069747 A1 AR 069747A1 AR P080105136 A ARP080105136 A AR P080105136A AR P080105136 A ARP080105136 A AR P080105136A AR 069747 A1 AR069747 A1 AR 069747A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- description
- antibodies
- methods
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Se proporcionan también moléculas de ácido nucleico que codifican los anticuerpos de esta descripcion, vectores de expresion, células hospedadoras y métodos para expresion de los anticuerpos de esta descripcion. Se proporcionan también inmunoconjugados, con inclusion de conjugados anticuerpo-fármaco, moléculas biespecíficas y composiciones farmacéuticas que comprenden los anticuerpos de esta descripcion. Esta descripcion proporciona también métodos para tratamiento del cáncer. Reivindicacion 1: Un conjugado anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano, o una porcion de fijacion de antígeno del mismo, en donde el anticuerpo fija B7-H4 humana y el conjugado anticuerpo-molécula asociada exhibe al menos una de las propiedades siguientes: (a) se fija a B7-H4 humana con una afinidad de 1 x 10-8 M o menos; o (b) inhibe el crecimiento de las células que expresan B7-H4 in vivo cuando se conjuga a una citotoxina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99169307P | 2007-11-30 | 2007-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069747A1 true AR069747A1 (es) | 2010-02-17 |
Family
ID=40427123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105136A AR069747A1 (es) | 2007-11-30 | 2008-11-26 | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
Country Status (15)
Country | Link |
---|---|
US (1) | US20110085970A1 (es) |
EP (1) | EP2224958A2 (es) |
JP (1) | JP2011505372A (es) |
KR (1) | KR20100093578A (es) |
CN (1) | CN101951959A (es) |
AR (1) | AR069747A1 (es) |
AU (1) | AU2008334063A1 (es) |
BR (1) | BRPI0818963A2 (es) |
CA (1) | CA2706926A1 (es) |
CL (1) | CL2008003526A1 (es) |
EA (1) | EA201000910A1 (es) |
IL (1) | IL205993A0 (es) |
MX (1) | MX2010005830A (es) |
TW (1) | TW200938224A (es) |
WO (1) | WO2009073533A2 (es) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5714212B2 (ja) | 2005-12-08 | 2015-05-07 | メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. | O8eに対するヒトモノクローナル抗体 |
JP5211790B2 (ja) * | 2007-03-26 | 2013-06-12 | 住友化学株式会社 | Dnaメチル化測定方法 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EP2350129B1 (en) | 2008-08-25 | 2015-06-10 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
ES2647317T3 (es) | 2008-11-03 | 2017-12-20 | Syntarga B.V. | Análogos de CC-1065 y sus conjugados |
MX2012001417A (es) | 2009-07-31 | 2012-07-03 | Organon Nv | Anticuerpos completamente humanos para atenuante de linfocitos b y t (btla). |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス,インコーポレーテッド | B7−h3と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
PT3108886T (pt) | 2010-04-21 | 2020-08-27 | Syntarga Bv | Conjugados de analógicos cc-1065 e ligantes bifuncionais |
TWI538918B (zh) | 2010-10-20 | 2016-06-21 | 財團法人工業技術研究院 | 人源化之單株抗體、其核苷酸序列與其用途 |
WO2012145568A1 (en) * | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
WO2013019906A1 (en) | 2011-08-01 | 2013-02-07 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
IN2014CN04961A (es) * | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
PL2836234T3 (pl) | 2012-04-12 | 2020-02-28 | Yale University | Podłoża do kontrolowanego dostarczania różnych środków farmaceutycznych |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
JP2016505843A (ja) * | 2012-12-19 | 2016-02-25 | アンプリミューン, インコーポレイテッド | B7−h4特異的抗体、並びにその組成物及び使用方法 |
EP2954327A1 (en) | 2013-02-07 | 2015-12-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
PE20151672A1 (es) * | 2013-03-14 | 2015-11-27 | Genentech Inc | Anticuerpos e inmunoconjugados anti-b7-h4 |
WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
AU2014299561B2 (en) * | 2013-06-24 | 2017-06-08 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
PT3030262T (pt) | 2013-08-08 | 2019-12-11 | Inst Gustave Roussy Igr | Composição farmacêutica de associação |
AU2014342004B2 (en) | 2013-11-01 | 2017-10-26 | Yale University | Modular particles for immunotherapy |
LT3092010T (lt) | 2014-01-10 | 2018-10-25 | Synthon Biopharmaceuticals B.V. | Metodas, skirtas gryninimui cys-sujungtų antikūno-vaisto konjugatų |
CN103981150B (zh) * | 2014-03-28 | 2016-06-01 | 苏州大学 | 抗人b7-h4单克隆抗体及其制备和应用 |
KR101923326B1 (ko) | 2014-06-06 | 2018-11-29 | 브리스톨-마이어스 스큅 컴퍼니 | 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
EP3169361B1 (en) | 2014-07-15 | 2019-06-19 | F.Hoffmann-La Roche Ag | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
TW201625689A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗-b7-h4抗體及免疫結合物 |
WO2016070001A1 (en) * | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
UY36404A (es) | 2014-11-21 | 2016-06-01 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN |
CA2968382A1 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
EP4249066A3 (en) | 2014-12-23 | 2023-11-22 | Bristol-Myers Squibb Company | Antibodies to tigit |
RS60753B1 (sr) | 2015-04-17 | 2020-10-30 | Bristol Myers Squibb Co | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
TW201709929A (zh) | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | 治療癌症的聯合療法 |
GEP20227419B (en) | 2015-07-30 | 2022-10-10 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
AU2016334041B2 (en) | 2015-10-08 | 2023-02-09 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
EP3377532B1 (en) | 2015-11-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2017106061A1 (en) | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
KR20230038311A (ko) | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
WO2017155981A1 (en) | 2016-03-07 | 2017-09-14 | Massachusetts Institute Of Technology | Protein-chaperoned t-cell vaccines |
BR112018071105A2 (pt) | 2016-04-15 | 2019-02-26 | Macrogenics, Inc. | conjugado de droga e anticorpo, molécula de ligação, composição farmacêutica e uso |
SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
ES2905823T3 (es) | 2016-05-20 | 2022-04-12 | Biohaven Therapeutics Ltd | Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres |
CN109563503B (zh) * | 2016-07-26 | 2023-09-29 | 静冈县 | 抗b7-h4抗体 |
JP2019533645A (ja) | 2016-09-16 | 2019-11-21 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ |
WO2018099539A1 (en) * | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof |
AU2017367734A1 (en) | 2016-12-01 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-PD-l1 antibodies for immuno-PET imaging |
CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
EP3601355A1 (en) | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2018195302A1 (en) * | 2017-04-19 | 2018-10-25 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
KR20200006115A (ko) | 2017-05-16 | 2020-01-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-gitr 효능제 항체에 의한 암의 치료 |
KR20200013241A (ko) | 2017-05-25 | 2020-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
JP7437301B2 (ja) | 2017-08-25 | 2024-02-22 | ファイヴ プライム セラピューティクス インク | B7-h4抗体及びその使用方法 |
JP2020532537A (ja) | 2017-08-31 | 2020-11-12 | アイオー セラピューティクス インコーポレイテッド | がん免疫治療法のための免疫調節物質と併せたrar選択的アゴニスト |
JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 腫瘍処置法 |
US11946094B2 (en) | 2017-12-10 | 2024-04-02 | Augusta University Research Institute, Inc. | Combination therapies and methods of use thereof |
CN108148137B (zh) * | 2017-12-29 | 2021-03-23 | 中国人民解放军第四军医大学 | 一种b7h4/1e10单克隆抗体及其应用 |
US20210032346A1 (en) * | 2018-01-23 | 2021-02-04 | Nextcure, Inc. | B7-h4 antibodies and methods of use thereof |
BR112020015736A2 (pt) * | 2018-02-11 | 2020-12-08 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Anticorpo anti-b7-h4, fragmento de ligação a antígeno do mesmo e uso farmacêutico do mesmo |
CA3091174A1 (en) * | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
SG11202008105RA (en) | 2018-03-02 | 2020-09-29 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
JP2021519771A (ja) | 2018-03-30 | 2021-08-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 腫瘍を処置する方法 |
WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
WO2020047345A1 (en) | 2018-08-31 | 2020-03-05 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
CA3114955A1 (en) * | 2018-10-15 | 2020-04-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
WO2020140070A1 (en) * | 2018-12-27 | 2020-07-02 | Gigagen, Inc. | Anti-b7-h4 binding proteins and methods of use thereof |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
BR112021024406A2 (pt) * | 2019-06-06 | 2022-04-19 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Conjugado anticorpo-fármaco anti-b7-h4 e uso medicinal do mesmo |
MA56523A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 ou anti-pd-l1 |
AU2020296372A1 (en) | 2019-06-18 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 antibody |
WO2021108025A1 (en) | 2019-11-26 | 2021-06-03 | Massachusetts Institute Of Technology | Cell-based cancer vaccines and cancer therapies |
CN110981961B (zh) * | 2019-11-28 | 2022-07-29 | 青岛大学 | 一种特异结合癌细胞蛋白b7-h4的纳米抗体h6的序列和应用 |
EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
KR20220154757A (ko) | 2020-03-18 | 2022-11-22 | 젠맵 에이/에스 | B7h4에 결합하는 항체 |
CN115835856A (zh) | 2020-05-13 | 2023-03-21 | 麻省理工学院 | 聚合物微装置的组合物以及其在癌症免疫疗法中的用途 |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
TWI821699B (zh) * | 2020-06-30 | 2023-11-11 | 大陸商諾納生物(蘇州)有限公司 | 抗b7h4抗體及其雙抗和應用 |
US20230235090A1 (en) * | 2020-06-30 | 2023-07-27 | Harbour Biomed US, Inc. | Bispecific antibody and use thereof |
AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
WO2022147532A1 (en) | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
WO2022165403A1 (en) | 2021-02-01 | 2022-08-04 | Yale University | Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment |
CA3207652A1 (en) | 2021-03-26 | 2022-09-29 | Stephanie Cornen | Cytokine anchors for nkp46-binding nk cell engager proteins |
US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
IL308300A (en) | 2021-05-07 | 2024-01-01 | Genmab As | Pharmaceutical preparations containing bispecific antibodies that bind to B7H4 and CD3 |
EP4352098A1 (en) | 2021-06-09 | 2024-04-17 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2023278641A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
CA3228682A1 (en) * | 2021-08-18 | 2023-02-23 | Harbour Biomed (Shanghai) Co., Ltd | Anti-b7-h4 antibody, and preparation method therefor and use thereof |
US20240050585A1 (en) * | 2022-05-17 | 2024-02-15 | Mersana Therapeutics, Inc. | B7-h4-targeted antibody-drug conjugates for the treatment of cancer |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024040264A1 (en) | 2022-08-19 | 2024-02-22 | Massachusetts Institute Of Technology | Compositions and methods for targeting dendritic cell lectins |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2459308A1 (en) * | 2001-09-07 | 2003-03-20 | Dale L. Boger | Cbi analogues of cc-1065 and the duocarmycins |
CA2546054C (en) * | 2003-12-10 | 2014-05-13 | Medarex, Inc. | Interferon alpha antibodies and their uses |
CA2564076C (en) * | 2004-05-19 | 2014-02-18 | Medarex, Inc. | Chemical linkers and conjugates thereof |
WO2007038658A2 (en) * | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
JP5714212B2 (ja) * | 2005-12-08 | 2015-05-07 | メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. | O8eに対するヒトモノクローナル抗体 |
US9121853B2 (en) * | 2006-03-20 | 2015-09-01 | Mayo Foundation For Medical Education And Research | B7-H4 expression on tumor vasculature |
TWI412367B (zh) * | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
-
2008
- 2008-11-26 JP JP2010536180A patent/JP2011505372A/ja active Pending
- 2008-11-26 CL CL2008003526A patent/CL2008003526A1/es unknown
- 2008-11-26 US US12/745,677 patent/US20110085970A1/en not_active Abandoned
- 2008-11-26 AU AU2008334063A patent/AU2008334063A1/en not_active Abandoned
- 2008-11-26 CN CN2008801258530A patent/CN101951959A/zh active Pending
- 2008-11-26 TW TW097145818A patent/TW200938224A/zh unknown
- 2008-11-26 EA EA201000910A patent/EA201000910A1/ru unknown
- 2008-11-26 MX MX2010005830A patent/MX2010005830A/es not_active Application Discontinuation
- 2008-11-26 KR KR1020107014485A patent/KR20100093578A/ko not_active Application Discontinuation
- 2008-11-26 WO PCT/US2008/084923 patent/WO2009073533A2/en active Application Filing
- 2008-11-26 CA CA2706926A patent/CA2706926A1/en not_active Abandoned
- 2008-11-26 EP EP08858252A patent/EP2224958A2/en not_active Withdrawn
- 2008-11-26 BR BRPI0818963 patent/BRPI0818963A2/pt not_active IP Right Cessation
- 2008-11-26 AR ARP080105136A patent/AR069747A1/es unknown
-
2010
- 2010-05-26 IL IL205993A patent/IL205993A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008334063A2 (en) | 2011-01-20 |
MX2010005830A (es) | 2010-09-14 |
AU2008334063A1 (en) | 2009-06-11 |
KR20100093578A (ko) | 2010-08-25 |
US20110085970A1 (en) | 2011-04-14 |
EA201000910A1 (ru) | 2011-04-29 |
CN101951959A (zh) | 2011-01-19 |
JP2011505372A (ja) | 2011-02-24 |
IL205993A0 (en) | 2010-11-30 |
EP2224958A2 (en) | 2010-09-08 |
TW200938224A (en) | 2009-09-16 |
BRPI0818963A2 (pt) | 2015-05-05 |
CL2008003526A1 (es) | 2010-01-11 |
WO2009073533A2 (en) | 2009-06-11 |
CA2706926A1 (en) | 2009-06-11 |
WO2009073533A3 (en) | 2009-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
AR064360A1 (es) | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos | |
AR064109A1 (es) | Anticuerpos humanos que se enlazan al cd22 y sus usos | |
AR069903A1 (es) | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer | |
AR050642A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina | |
MX2010008570A (es) | Anticuerpos alfa5-beta1 y sus usos. | |
AR063086A1 (es) | Anticuerpos humanos que se unen a cxcr4 y usos de los mismos | |
EA200801509A1 (ru) | Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7 | |
NZ595574A (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
CO6300960A2 (es) | Anticuerpos humanos enlazantes de mesotelina y usos de los mismos | |
BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
SG170080A1 (en) | Human monoclonal antibodies to o8e | |
AR069981A1 (es) | Los "anticuerpo modificado geneticamente que reconocen cd138". | |
ATE478094T1 (de) | Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate,die diese enthalten | |
WO2007067992A3 (en) | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 | |
AR059809A1 (es) | Anticuerpos anti-5t4 y sus usos | |
EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
BR112012011268A2 (pt) | anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos | |
EA201270654A1 (ru) | Моноклональные антитела, связывающие b7h6, и их применение | |
EA200800952A1 (ru) | Конъюгаты антитело-лекарство и способы применения | |
PA8626201A1 (es) | Conjugados de caliqueamicina | |
MX2020011554A (es) | Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19). | |
EA200870615A1 (ru) | Производные лептомицина | |
BRPI0817427A8 (pt) | anticorpo anti-bst2 | |
WO2008045976A3 (en) | Compositions and methods for treating and diagnosing cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |